A Phase I Study of TNP-470 in the Treatment of AIDS-Associated Kaposi's Sarcoma

Inclusion Criteria Concurrent Medication: Allowed: * AZT, ddI, ddC, or d4T provided patients have received at least 2 weeks of this therapy prior to study entry. (Combination ddI/ddC is not permitted.) * MAI prophylaxis. Required in patients with CD4 count \< 200 cells/mm3: Aerosolized pentamidine, trimethoprim/sulfamethoxazole, or dapsone as PCP prophylaxis. Patients must have: * HIV infection. * Cutaneous Kaposi's sarcoma. * Life expectancy of at least 3 months. * Consent of parent or guardian if under 18 years of age. NOTE: * This protocol is considered suitable for prison populations. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: * Peripheral neuropathy (grade 2 or worse). * Underlying severe or life-threatening infection with bacterial, viral, fungal, or protozoal pathogens. * Known hypersensitivity to TNP-470, fumagillin, or known related compounds. PER AMENDMENT 9/3/96: * Cataracts. Concurrent Medication: Excluded: * Combination therapy with ddI/ddC (although these drugs may be administered alone or in combination with AZT). * Anticonvulsive medication. * Steroids. * Antineoplastic drugs. * Interferons. * Systemic or topical anti-Kaposi's sarcoma agents or regimens. * Suramin. * Aspirin. * Warfarin. * Heparin (including heparin flushes). * Nonsteroidal anti-inflammatory drugs. * Investigational status drugs. Patients with the following prior conditions are excluded: * History of substantial non-iatrogenic bleeding disorders. * History of tumor or malignancies other than Kaposi's sarcoma, with the exception of completely resected basal cell skin carcinoma or in situ cervical carcinoma. * History of seizures within the past 10 years. PER AMENDMENT 9/3/96: * History of cataracts. Prior Medication: Excluded within 4 weeks prior to study entry: * Steroids. * Antineoplastic drugs. * Interferons. * Systemic or topical anti-Kaposi's sarcoma agents or regimens. Excluded within 6 months prior to study entry: * Suramin. Unwilling to refrain from unprotected sexual contact or other activities that may result in HIV re-infection.